The future research with LC.Abbreviations CKD-MBD: Chronic kidney disease mineral and bone disorder; ESRD: End-stage renal illness; LC: Lanthanum carbonate; RCT: Randomized controlled trials; iPTH: Intact parathyroid hormone; CC: Calcium carbonate; SH: Sevelamer hydrochlorid; CV: Cardiovascular; HD: Hemodialysis; CAPD: Continuous ambulatory peritoneal dialysis; CENTRAL: Cochrane Central Register of Controlled Trials; CBBs: Calcium-based binders; NCBs: Non-calcium binders; CT: Computed tomography; TAP: Total alkaline phosphatase; BAP: Bone-specific alkaline phosphatase); RR: Danger ratios; CI: Self-assurance intervals; MD: Mean distinction; SMD: Standardised mean difference; ROD: Renal osteodystrophy; DCOR: Dialysis Clinical Outcomes Revisited.Zhang et al. BMC Nephrology 2013, 14:226 http://www.biomedcentral/1471-2369/14/Page 13 ofCompeting interests The authors declared that they have no competing interests. Authors’ contributions ZCL was involved in conducting the literature searches, obtained and analysed studies and wrote the manuscript of the paper. WJ was involved in conducting the literature searches, obtained and analysed research. LZ was involved within the design and style with the study, adjudication on disagreements in data evaluation, writing and editing of draft and final versions in the paper. FJM was involved inside the design and style on the study. All authors have read and approved the final manuscript. Acknowledgements The authors would prefer to acknowledge Professor Guanjian Liu in EvidenceBased Medicine Center of China, for his assistance in the conduct of this systematic evaluation. The authors would also prefer to acknowledge Professor Takashi Shigematsu and Professor Maki Morikawa who supply the detailed data to this systematic overview. Author information 1 Division of nephrology, West China Hospital of Sichuan University, Chengdu, China. 2Luzhou Healthcare College, Luzhou, China. Received: 23 April 2013 Accepted: 11 October 2013 Published: 17 October 2013 References 1. Moe S, Dr ke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G, Kidney Illness: Improving Worldwide Outcomes (KDIGO): Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Illness: Enhancing Global Outcomes (KDIGO).Luminol manufacturer Kidney Int 2006, 69:1945953. 2. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL: Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in individuals with chronic kidney illness: results on the study to evaluate early kidney disease. Kidney Int 2007, 71(1):318. three. Block GA, Pork FK: Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for any modify in management. Am J Kidney Dis 2000, 35:1226237.N-Acetyl-L-aspartic acid manufacturer four.PMID:24818938 Palmer SC, Hayen A, Macaskill P, Pellegrini F, Craig JC, Elder GJ, Strippoli GF: Serum levels of phosphorus, parathyroid hormone, and calcium and dangers of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA 2011, 305(11):1119127. five. Wald R, Sarnak MJ, Tighiouart H, Cheung AK, Levey AS, Eknoyan G, Miskulin DC: Disordered mineral metabolism in hemodialysis sufferers: an evaluation of cumulative effects within the Hemodialysis (HEMO) Study. Am J Kidney Dis 2008, 52:53140. 6. Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, Young EW, Akizawa T, Akiba T, Pisoni RL, Robinson BM, Port FK: Mortality threat for dialysis patients with differen.